Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Details)

v2.4.0.8
Condensed Consolidated Financial Statement Detail (Details)
3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended
Mar. 31, 2014
USD ($)
Mar. 31, 2013
Dec. 31, 2013
USD ($)
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
USD ($)
Mar. 31, 2014
Five year warrants issued in February 2010 [Member]
USD ($)
Dec. 31, 2013
Five year warrants issued in February 2010 [Member]
USD ($)
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
Mar. 31, 2014
Five year warrants issued in March 2012 [Member]
USD ($)
Mar. 31, 2014
Five year warrants issued in March 2012 [Member]
Dec. 31, 2013
Five year warrants issued in March 2012 [Member]
USD ($)
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
Jun. 30, 2009
Warrants issued to private investors [Member]
USD ($)
Mar. 31, 2014
Warrants issued to private investors [Member]
USD ($)
Jun. 30, 2009
Warrants issued to private investors [Member]
Mar. 31, 2014
Options Contract [Member]
USD ($)
Contract
Mar. 31, 2013
Options Contract [Member]
USD ($)
Mar. 31, 2014
Options Contract [Member]
EUR (€)
Mar. 31, 2014
Option Contract 1 [Member]
EUR (€)
Mar. 31, 2014
Option Contract 2 [Member]
EUR (€)
Mar. 31, 2014
Demand Deposits [Member]
USD ($)
Dec. 31, 2013
Demand Deposits [Member]
USD ($)
Mar. 31, 2014
Money Market Funds [Member]
USD ($)
Dec. 31, 2013
Money Market Funds [Member]
USD ($)
Mar. 31, 2014
Common stock options and restricted stock units [Member]
Mar. 31, 2013
Common stock options and restricted stock units [Member]
Mar. 31, 2014
Warrants for common stock [Member]
Mar. 31, 2013
Warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                                                        
Antidilutive securities excluded from computation of earnings per share (in shares) 20,005,000 22,635,000                                             5,732,000 6,459,000 14,273,000 16,176,000
Cash and Cash Equivalents [Line Items]                                                        
Cash equivalents                                         $ 10,100,000 $ 18,900,000 $ 63,600,000 $ 82,800,000        
Short-term Investments [Abstract]                                                        
Short-term investments, U.S. treasury securities 19,996,000   19,990,000 [1]                                                  
Derivative [Line Items]                                                        
Notional amount of derivative liability                                   15,000,000                    
Number of foreign exchange option contracts                               2                        
Derivative, amount of hedged item                                     1,500,000 15,000,000                
Derivative, premiums                               1,500,000                        
Derivative fair value                               200,000                        
Derivative, loss                               100,000 200,000                      
Accrued liabilities [Abstract]                                                        
Accrued payroll and other benefits 2,401,000   3,009,000                                                  
Accrued management incentive compensation 1,050,000   4,386,000                                                  
Other 1,444,000   2,539,000                                                  
Total 4,895,000   9,934,000 [1]                                                  
Class of Warrant or Right [Line Items]                                                        
Warrants outstanding (in shares)             1,260,000     12,109,418   14,834,577     347,826                          
Exercise price (in dollars per share)       $ 10.50       $ 1.76         $ 19.50                              
Fair value of warrant liability           1,200,000     46,600,000   68,700,000     700,000                            
Gain (loss) on revaluation of warrant liability         500,000       19,500,000                                      
Warrant Term       5 years       5 years         5 years                              
Reclassification of warrant liability to equity $ 2,500,000                                                      
[1] (Note 1) The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.